Skip to Content
Merck
All Photos(1)

Key Documents

SML3224

Sigma-Aldrich

Sugammadex sodium

≥95% (HPLC), powder, neuromuscular blocker reversing agent

Synonym(s):

6-Perdeoxy-6-per(2-carboxyethyl)thio-γ-cyclodextrin, sodium Salt, Org 25969, Org-25969, Org25969

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C72H104Na8O48S8
CAS Number:
Molecular Weight:
2178.01
MDL number:
UNSPSC Code:
12352107
NACRES:
NA.77

product name

Sugammadex sodium, ≥95% (HPLC)

Quality Level

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@@H]3[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O[C@@H]5[C@@H](CSCCC(O[Na])=O)O[C@H](O[C@@H]6[C@@H](CSCCC(O[Na])=O)O[C@H]7[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)O[C@@H]4CSCCC(O[Na])

InChI

1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-;;;;;;;;/m1......../s1

InChI key

KMGKABOMYQLLDJ-VKHHSAQNSA-F

Biochem/physiol Actions

Sugammadex (Org 25969) is a selective relaxant binding agent (SRBA) for complexing aminosteroid nonpolarizing neuromuscular blockers (NMBs), including pipecuronium, rocuronium and vecuronium. Sugammadex effectively recovers muscle twitch blockade in vitro (EC50 = 1.2 μM, Emax = 95.1%; isolated mouse hemi-diaphragm under 90% block by 3.6 μM rocuronium) and reverses neuromuscular blockade in vivo (ED50 = 30 nmol/kg i.v. & Emax = 92.5% with guinea pigs under 90% neuromuscular block by 10 nmol/kg/min rocuronium i.v. infusion; >90% recovery at 1 mg/kg or 0.46 μmol/kg i.v. of M. tibialis contractions of cats under 95% block by 10.24 nmol/kg/min rocuronium i.v. infusion).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yong Beom Kim et al.
Korean journal of anesthesiology, 73(3), 239-246 (2019-10-18)
In this study, we used an ex-vivo model to investigate the recovery pattern of both the train-of-four (TOF) ratio and first twitch tension of TOF (T1), and determined their relationship during recovery from rocuronium-induced neuromuscular blockade at various concentrations of
Seok Kyeong Oh et al.
Scientific reports, 9(1), 11268-11268 (2019-08-04)
Studies have reported that protracted dexamethasone treatment induces resistance to nondepolarizing neuromuscular blocking agents (NMBAs) and the association with nicotinic acetylcholine receptors in the diaphragm of rats. Here, we investigated the effect of protracted dexamethasone administration on the sensitivity to
Jae Moon Choi et al.
Journal of anesthesia, 33(6), 642-646 (2019-09-20)
Sugammadex is used to reverse neuromuscular block induced by rocuronium or vecuronium by forming a stable complex. If the binding capacity of any substance to sugammadex is large enough, this molecule will displace rocuronium or vecuronium from the complex. For
Ola Epemolu et al.
Anesthesiology, 99(3), 632-637 (2003-09-10)
The purpose of this study was to determine the changes in the plasma concentration of rocuronium and the reversal of its neuromuscular blockade after the intravenous infusion of Org 25969, the novel neuromuscular block-reversal agent, in anesthetized guinea pigs. Rocuronium
Julia M Adam et al.
Journal of medicinal chemistry, 45(9), 1806-1816 (2002-04-19)
A series of mono- and per-6-substituted cyclodextrin derivatives were synthesized as synthetic receptors (or host molecules) of rocuronium bromide, the most widely used neuromuscular blocker in anaesthesia. By forming host-guest complexes with rocuronium, these cyclodextrin derivatives reverse the muscle relaxation

Related Content

Explore protein pathway analysis through chemical library screening, investigating protein interactions, and modulating signaling pathways with small molecules.

Explore protein pathway analysis through chemical library screening, investigating protein interactions, and modulating signaling pathways with small molecules.

Explore protein pathway analysis through chemical library screening, investigating protein interactions, and modulating signaling pathways with small molecules.

Explore protein pathway analysis through chemical library screening, investigating protein interactions, and modulating signaling pathways with small molecules.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service